In early January, we told you that Big Pharma players were starting the New Year with $70 billion in cash on their balance sheets - meaning the "buyout binge" that started in 2012 was certain to carry over into 2013.
And that's just what's happened.
Faced with patent expirations on existing blockbuster drugs, and pipelines that are bereft of replacements, Big Pharma players have been all year long to buy companies outright, to buy product lines or R&D portfolios, or just to purchase individual drugs.
To continue reading, please click here...
This is premium content for Private Briefing subscribers only.
Money Morning's Executive Director Bill Patalon has discovered a unique backdoor way to reap huge profits - to the tune of 149% gains - from the Alibaba Shockwave Effect. This has nothing to do with the "obvious" companies that have been bandied about on the Internet. Bill's found a company that 99% of the U.S. population has never heard of before. And they're about to cash out big time. Click here before it's too late.